ProCE Banner Activity

Management Strategies for Treating Patients With NSCLC and Uncommon EGFR Mutations

Clinical Thought
What I want my colleagues to know about treating patients with advanced NSCLC and uncommon EGFR mutations, including future directions targeting these mutations.

Released: May 20, 2022

Expiration: May 19, 2023

No longer available for credit.

Share

Faculty

Joel W. Neal

Joel W. Neal, MD, PhD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Joel W. Neal, MD, PhD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

Joel W. Neal, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Blueprint, Calithera, D2G Oncology, Exelixis, Genentech/Roche, Iovance Biotherapeutics, Jounce Therapeutics, Lilly, Natera, Regeneron, Sanofi/Regeneron, Surface Oncology, Takeda, and Turning Point and funds for research support paid to his institution from AbbVie, Adaptimmune, Boehringer Ingelheim, Exelixis, Genentech/Roche, GlaxoSmithKline, Janssen, Merck, Nektar Therapeutics, Novartis, and Takeda.